Trial 1: Effect of MP-010 on neuromuscular outcomes
This trial was conducted at the animal facility of the Universitat Autònoma de Barcelona using the colony of SOD1G93Amice that has been bred over years by Dr. Navarro’s group. At 8 weeks of age (before drug treatment started), WT and SOD1G93Amice were distributed among 6 experimental groups, according to their progenitors, sex, weight, and electrophysiology baseline values in balanced groups, receiving either vehicle or MP-010 at two different doses. The compound MP-010 was added to the drinking water at concentrations of 1 mM or 2 mM, resulting in average daily dosages of 61 mg/kg or 122 mg/kg, respectively. The mice were distributed in six groups for assessment of neuromuscular outcomes: 1) WT vehicle, this group consists of WT mice with no treatment (n=4/4; females/males ); 2) WT MP-010 61 mg/kg (n=5/4); 3) WT MP-010 122 mg/kg (n=2/3); 4) SOD1G93A vehicle (n=8/8); 5) SOD1G93A MP-010 61 mg/kg (n=7/8); 6) SOD1G93A MP-010 122 mg/kg (n=5/4). The treatment was given from the 8th until the 16th week of age and electrophysiological, behavioral and histological analyses were performed during this follow-up.